BRYNJELSEN SEAN, PRES, CEO, reported a transaction classified as withholding at Eton Pharmaceuticals, Inc. involving 5015.000000 shares for an estimated $77180.85. Reported holdings after the transaction were 2889266.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
Form 4 relationship flags and nearby filing context
President & CEO
Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
The shares were sold in multiple trades at prices ranging from $15.39 to $15.42. The price reported above reflects the weighted average sales price.
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchase…
The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.
Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.
0 other filings
0 recent txs